A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)

Autor:	Pascale Andre, Norbert Vey, Anthony Gonçalves, Gilles Salles, Sophie Lebouvier-Sadot, Arnaud Pigneux, Dominique Berton-Rigaud, Robert Zerbib, Aude Charbonnier, Jaafar Bennouna, Florence Broussais, Lionel Karlin, Thomas Prebet, Nicolas Boissel, Delphine Marie, Renaud Buffet, Jerome Rey
Rok vydání:	2015
Předmět:	Cancer Research business.industry medicine.drug_class chemical and pharmacologic phenomena Human leukocyte antigen Monoclonal antibody Oncology Immunology Cancer research Dose escalation Medicine In patient business Receptor
Zdroj:	Journal of Clinical Oncology. 33:3065-3065
ISSN:	1527-7755 0732-183X
Popis:	3065 Background: Inhibitory Killer Immunoglobulin-like receptors (KIRs) negatively regulate the killing, by NK cells, of tumors expressing their HLA class I ligands. We showed safety of 1st generat...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::478439ef0e2d70ec5ddc8623fa93893d https://doi.org/10.1200/jco.2015.33.15_suppl.3065 Zobrazit plný text záznamu